Relationship between the inhibition constant (KI) and the concentration of inhibitor which causes 50 per cent inhibition (I50) of an enzymatic reaction

The kinetics of enzyme-catalyzed reactions with two or more substrates or products☆I. Nomenclature and rate equations

Cleland, W. W. (1963) · Biochimica et Biophysica Acta · doi:10.1016/0006-3002(63)91800-6 · Cited by 2,092

The kinetics of enzyme-catalyzed reactions with two or more substrates or products

Cleland, W. W. (1963) · Biochimica et Biophysica Acta (BBA) - Specialized Section on Enzymological Subjects · doi:10.1016/0926-6569(63)90211-6 · Cited by 1,915

Enzyme and metabolic inhibitors

Webb, J. L. (1963) · Academic Press eBooks · doi:10.5962/bhl.title.7320 · Cited by 1,529

The Biochemistry of Folic Acid and Related Pteridines.

(1970) · Annals of Internal Medicine · doi:10.7326/0003-4819-72-1-153_1 · Cited by 1,027

The kinetics of enzyme-catalyzed reactions with two or more substrates or products☆II. Inhibition: Nomenclature and theory

Cleland, W. W. (1963) · Biochimica et Biophysica Acta · doi:10.1016/0006-3002(63)91815-8 · Cited by 867

The kinetics of enzyme-catalyzed reactions with two or more substrates or products

Cleland, W. W. (1963) · Biochimica et Biophysica Acta (BBA) - Specialized Section on Enzymological Subjects · doi:10.1016/0926-6569(63)90227-x · Cited by 851

The kinetics of enzyme-catalyzed reactions with two or more substrates or products

Cleland, W. W. (1963) · Biochimica et Biophysica Acta (BBA) - Specialized Section on Enzymological Subjects · doi:10.1016/0926-6569(63)90226-8 · Cited by 790

ENZYME AND METABOLIC INHIBITORS

Fisher, R. B. (1964) · Quarterly Journal of Experimental Physiology and Cognate Medical Sciences · doi:10.1113/expphysiol.1964.sp001725 · Cited by 552

The kinetics of enzyme-catalyzed reactions with two or more substrates or products☆III. Prediction of initial velocity and inhibition patterns by inspection

Cleland, W. W. (1963) · Biochimica et Biophysica Acta · doi:10.1016/0006-3002(63)91816-x · Cited by 519

Design of Active-Site-Directed Irreversible Enzyme Inhibitors.

Burger, A. (1967) · Journal of Medicinal Chemistry · doi:10.1021/jm00318a065 · Cited by 389

From primordial clocks to circadian oscillators

Pitsawong, W., Pádua, R. A. P., Grant, T., Hoemberger, M., Otten, R., Bradshaw, N., Grigorieff, N., & Kern, D. (2023) · Nature · doi:10.1038/s41586-023-05836-9 · Cited by 37

Creating Diverse Target-Binding Surfaces on FKBP12: Synthesis and Evaluation of a Rapamycin Analogue Library

Wu, X., Wang, L., Han, Y., Regan, N., Li, P.-K., Villalona, M. A., Hu, X., Briesewitz, R., & Pei, D. (2011) · ACS Combinatorial Science · doi:10.1021/co200057n · Cited by 36

Effects of Pyridine Ring Substitutions on Affinity, Efficacy, and Subtype Selectivity of Neuronal Nicotinic Receptor Agonist Epibatidine

Avalos, M., Parker, M. J., Maddox, F. N., Carroll, F. I., & Luetje, C. W. (2002) · The Journal of Pharmacology and Experimental Therapeutics · doi:10.1124/jpet.102.035899 · Cited by 36

Mutual regulation of vasopressin- and oxytocin-induced glucagon secretion in V1b vasopressin receptor knockout mice

Fujiwara, Y., Hiroyama, M., Sanbe, A., Yamauchi, J., Tsujimoto, G., & Tanoue, A. (2007) · Journal of Endocrinology · doi:10.1677/joe.1.06864 · Cited by 36

Biological characterization of rodent and human vasopressin V1breceptors using SSR-149415, a nonpeptide V1breceptor ligand

Gal, C. S.-L., Raufaste, D., Derick, S., Blankenstein, J., Allen, J., Pouzet, B., Pascal, M., Wagnon, J., & Ventura, M. A. (2007) · American Journal of Physiology-Regulatory, Integrative and Comparative Physiology · doi:10.1152/ajpregu.00062.2007 · Cited by 35

Novel Zinc-Attenuating Compounds as Potent Broad-Spectrum Antifungal Agents with In Vitro and In Vivo Efficacy

Cohrt, K. A. O., Marín, L., Kjellerup, L., Clausen, J. D., Dalby-Brown, W., Calera, J. A., & Winther, A.-M. L. (2018) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.02024-17 · Cited by 32

The human near‐term myometrial β3‐adrenoceptor but not the β2‐adrenoceptor is resistant to desensitisation after sustained agonist stimulation

Rouget, C., Breuiller‐Fouché, M., Mercier, F. J., Leroy, M. J., Loustalot, C., Naline, E., Frydman, R., Croci, T., Morcillo, E. J., Advenier, C., et al. (2004) · British Journal of Pharmacology · doi:10.1038/sj.bjp.0705616 · Cited by 31

Pharmacological Comparative Characterization of REL-1017 (Esmethadone-HCl) and Other NMDAR Channel Blockers in Human Heterodimeric N-Methyl-D-Aspartate Receptors

Bettini, E., Stahl, S. M., De Martin, S., Mattarei, A., Sgrignani, J., Carignani, C., Nola, S., Locatelli, P., Pappagallo, M., Inturrisi, C. E., et al. (2022) · Pharmaceuticals · doi:10.3390/ph15080997 · Cited by 31

Characterization of a novel vasopressin V1b receptor antagonist, V1B-30N, in animal models of anxiety-like and depression-like behavior

Hodgson, R. A., Mullins, D., Lu, S. X., Guzzi, M., Zhang, X., Bleickardt, C. J., Scott, J. D., Miller, M. W., Stamford, A. W., Parker, E. M., et al. (2014) · European Journal of Pharmacology · doi:10.1016/j.ejphar.2014.02.027 · Cited by 30

Concentration-response relationship of the α7 nicotinic acetylcholine receptor agonist FRM-17874 across multiple in vitro and in vivo assays

Stoiljkovic, M., Leventhal, L., Chen, A., Chen, T., Driscoll, R., Flood, D., Hodgdon, H., Hurst, R., Nagy, D., Piser, T., et al. (2015) · Biochemical Pharmacology · doi:10.1016/j.bcp.2015.07.006 · Cited by 29

Structural similitudes between cytotoxic antiestrogen-binding site (AEBS) ligands and cytotoxic sigma receptor ligands. evidence for a relationship between cytotoxicity and affinity for AEBS or sigma-2 receptor but not for sigma-1 receptor

Kedjouar, B., Daunes, S., Vilner, B. J., Bowen, W. D., Klaebe, A., Faye, J.-C., & Poirot, M. (1999) · Biochemical Pharmacology · doi:10.1016/s0006-2952(99)00285-3 · Cited by 27

11-Oxygenated estrogens are a novel class of human estrogens but do not contribute to the circulating estrogen pool

Barnard, L., Schiffer, L., Louw du-Toit, R., Tamblyn, J. A., Chen, S., Africander, D., Arlt, W., Foster, P. A., & Storbeck, K.-H. (2021) · Endocrinology · doi:10.1210/endocr/bqaa231 · Cited by 27

The N-terminal juxtamembrane segment of the V1a vasopressin receptor provides two independent epitopes required for high-affinity agonist binding and signaling

Hawtin, S. R., Wesley, V. J., Simms, J., Argent, C. C. H., Latif, K., & Wheatley, M. (2005) · Molecular Endocrinology · doi:10.1210/me.2005-0148 · Cited by 24

Free enthalpies of replacing water molecules in protein binding pockets.

Riniker, S., Barandun, L. J., Diederich, F., Krämer, O., Steffen, A., & van Gunsteren, W. F. (2012) · Journal of Computer-Aided Molecular Design · doi:10.1007/s10822-012-9620-8 · Cited by 23

Interaction of Approved Drugs with Synaptic Vesicle Protein 2A

Danish, A., Namasivayam, V., Schiedel, A. C., & Müller, C. E. (2017) · Archiv der Pharmazie · doi:10.1002/ardp.201700003 · Cited by 19

Influence of exercise and age on myocardial β-adrenergic receptor properties

Scarpace, P. J., Lowenthal, D. T., & Tümer, N. (1992) · Experimental Gerontology · doi:10.1016/0531-5565(92)90041-w · Cited by 18

A combined α7 nicotinic acetylcholine receptor agonist and monoamine reuptake inhibitor, NS9775, represents a novel profile with potential benefits in emotional and cognitive disturbances

Andreasen, J. T., Redrobe, J. P., Nielsen, E. Ø., Christensen, J. K., Olsen, G. M., & Peters, D. (2013) · Neuropharmacology · doi:10.1016/j.neuropharm.2013.04.060 · Cited by 15

In vitro affinity maturation of antibody against membrane-bound GPCR molecules

Wang, J., An, L., Zhao, Y., Zhang, C., Li, S., Ye, C., Jing, S., & Hang, H. (2019) · Applied Microbiology and Biotechnology · doi:10.1007/s00253-019-10030-x · Cited by 11

Degronomics: Mapping the Interacting Peptidome of a Ubiquitin Ligase Using an Integrative Mass Spectrometry Strategy

Canzani, D., Rusnac, D.-V., Zheng, N., & Bush, M. F. (2019) · Analytical Chemistry · doi:10.1021/acs.analchem.9b02331 · Cited by 11

Development Assay for of a 5-Hydroxytryptamine2A Receptor Binding High Throughput Screening Using 96-Well Microfilter Plates

Harms, A., Gündisch, D., Müller, C. E., & Kovar, K.-A. (2000) · SLAS Discovery · doi:10.1177/108705710000500410 · Cited by 8

Trypstatin as a Novel TMPRSS2 Inhibitor with Broad‐Spectrum Efficacy against Corona and Influenza Viruses

Lawrenz, J., Wettstein, L., Rodríguez Alfonso, A., Nchioua, R., von Maltitz, P., Albers, D. P. J., Zech, F., Vandeput, J., Naesens, L., Fois, G., et al. (2025) · Advanced Science · doi:10.1002/advs.202506430 · Cited by 8

Inhibition and Inactivation of Enzymes

Buxbaum, E. (2015) · Springer eBooks · doi:10.1007/978-3-319-19920-7_6 · Cited by 2

Protein Function | Kinetics of Enzyme Inhibition

Waldrop, G. L. (2020) · Elsevier eBooks · doi:10.1016/b978-0-12-819460-7.00027-x

A qualitative approach to enzyme inhibition

Waldrop, G. L. (2009) · Biochemistry and Molecular Biology Education · doi:10.1002/bmb.20243 · Cited by 65

Steady-state kinetics of one-substrate enzymic mechanisms involving two enzyme conformations I. Effects of modifiers on a mechanism postulating a single enzyme-substrate complex

Cennamo, C. (1968) · Journal of Theoretical Biology · doi:10.1016/0022-5193(68)90074-x · Cited by 12

Enzyme kinetics: partial and complete uncompetitive inhibition

Whiteley, C. G. (2000) · Biochemical Education · doi:10.1111/j.1539-3429.2000.tb00050.x · Cited by 16